Stay updated on NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial page.

Latest updates to the NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial page
- Check4 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a clinical trial for recurrent squamous cell head and neck tumors, which included specifics about the study's design, eligibility criteria, and treatment protocols. Additionally, there are new disclaimers regarding the security of the website and its official status as a U.S. government site.SummaryDifference100%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check19 days agoChange DetectedA service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1%
- Check26 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference1%
- Check47 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
Stay in the know with updates to NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NC-6004+Pembrolizumab Combination in Head & Neck Cancer Clinical Trial page.